Protein Modification Reagents
eMolecules 1924596-31-5 | Mal-amido-PEG8-TFP ester | Broadpharm | MFCD28505514 | 740.699 | C32H44F4N2O13 | 98.000 | Fc1cc(F)c(F)c(OC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCNC(=O)CCN2C(=O)C=CC2=O)c1F | 500mg | 279709072
Mal-amido-PEG8-TFP ester | Broadpharm | 1924596-31-5 | MFCD28505514 | 740.699 | C32H44F4N2O13 | 98.000 | Fc1cc(F)c(F)c(OC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCNC(=O)CCN2C(=O)C=CC2=O)c1F | 500mg | 279709072
eMolecules 2401832-00-4 | Thalidomide-O-PEG4-Amine | Broadpharm493.513 | C23H31N3O9 | 95.000 | NCCOCCOCCOCCOCCOc1cccc2C(=O)N(C3CCC(=O)NC3=O)C(=O)c12 | 500mg | 550804639
Thalidomide-O-PEG4-Amine | Broadpharm | 2401832-00-4493.513 | C23H31N3O9 | 95.000 | NCCOCCOCCOCCOCCOc1cccc2C(=O)N(C3CCC(=O)NC3=O)C(=O)c12 | 500mg | 550804639
eMolecules 17-(Bromoacetamido-PEG9-ethylcarbamoyl)nonanoic t-butyl ester | Broadpharm |817.853 | C36H69BrN2O13 | 98.000 | CC(C)(C)OC(=O)CCCCCCCCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCNC(=O)CBr | 250mg | 490840982
17-(Bromoacetamido-PEG9-ethylcarbamoyl)nonanoic t-butyl ester | Broadpharm |817.853 | C36H69BrN2O13 | 98.000 | CC(C)(C)OC(=O)CCCCCCCCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCNC(=O)CBr | 250mg | 490840982
CCOCCOCCOCCOCCN1C(=O)C=CC1=O)C(=O)N[C@@H](CCCNC(N)=O)C(=O)Nc1ccc(COC(=O)Oc2ccc(cc2)[N+]([O-])=O)cc1 | 50mg | 349512600](https://assets.fishersci.com/TFS-Assets/CCG/product-images/NC1657551.jpg-250.jpg)
eMolecules 2112738-09-5 | Mal-PEG4-Val-Cit-PAB-PNP | Broadpharm | MFCD30828694 | 871.898 | C40H53N7O15 | 0.000 | CC(C)[C@H](NC(=O)CCOCCOCCOCCOCCN1C(=O)C=CC1=O)C(=O)N[C@@H](CCCNC(N)=O)C(=O)Nc1ccc(COC(=O)Oc2ccc(cc2)[N+]([O-])=O)cc1 | 50mg | 349512600
Mal-PEG4-Val-Cit-PAB-PNP | Broadpharm | 2112738-09-5 | MFCD30828694 | 871.898 | C40H53N7O15 | 0.000 | CC(C)[C@H](NC(=O)CCOCCOCCOCCOCCN1C(=O)C=CC1=O)C(=O)N[C@@H](CCCNC(N)=O)C(=O)Nc1ccc(COC(=O)Oc2ccc(cc2)[N+]([O-])=O)cc1 | 50mg | 349512600
Medchemexpress LLC m-PEG2-CH2CH2COOH | 209542-49-4 | MFCD20646047 | ≥97.0% | 192.21 g/mol | C8H16O5 | 5 G
m-PEG2-CH2CH2COOH is a PEG-based PROTAC linker used in the synthesis of proteolysis targeting chimeras (PROTACs). It provides a short, flexible polyethylene glycol spacer terminating in a carboxylic acid group for conjugation and linkage in medicinal chemistry research.
- Short PEG2 spacer terminating in a carboxylic acid for conjugation.
- Suitable for use as a PROTAC linker in medicinal chemistry applications.
- Available in multiple sizes for synthesis scale flexibility, including 5 G.
- Characterized by CAS 209542-49-4 and molecular weight 192.21 g/mol.
TARGETMOL CHEMICALS INC S R S-AHPC-PEG1-N3 10MG
Also available in 1 mL, 1 mg, 5 mg, 25 mg, 50 mg, 100 mg, 200 mg and bulk. Please contact Fisher for quotes. (S,R,S)-AHPC-PEG1-N3 (E3 ligase Ligand-Linker Conjugates 3) is a synthesized E3 ligase ligand-linker conjugate that includes the (S,R,S)-AHPC-based VHL ligand and a 1-unit PEG linker used in PROTAC technology.
Medchemexpress LLC Plga-peg-mal (60kda-3.4kda, la:ga ratio 75:25) | 95.0% | 60kDA-3.4kDA | 50 MG
PLGA-PEG-MAL (60kDA-3.4kDA, LA:GA ratio 75:25) is a poly(lactide-co-glycolide)-block-poly(ethylene glycol) (PLGA-PEG-Mal) nanoparticle. It has a molecular weight range of 60kDA to 3.4kDA and a 75:25 lactic acid (LA) to glycolic acid (GA) ratio. This product is for research use only.
- Type: poly(lactide-co-glycolide)-block-poly(ethylene glycol) nanoparticles
- Molecular weight: 60kDA to 3.4kDA
- Lactic acid to glycolic acid ratio: 75:25
- Purity: 95.0%
- Appearance: solid
- Color: white to off-white
- Storage: powder at -20°C for 3 years or 4°C for 2 years; in solvent at -80°C for 6 months or -20°C for 1 month
- Solubility in DMSO: 100 mg/mL
(=O)OCCNC(=O)OCCOC)OC(=O)CCCCCCCCCCCCCCCCC | 250mg | 672544474](https://assets.fishersci.com/TFS-Assets/CCG/product-images/502465870.JPG-250.jpg)
eMolecules m-PEG-DSPE, MW 3,000 | Broadpharm |850.169 | C45H88NO11P | 90.000 | CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCNC(=O)OCCOC)OC(=O)CCCCCCCCCCCCCCCCC | 250mg | 672544474
m-PEG-DSPE, MW 3,000 | Broadpharm |850.169 | C45H88NO11P | 90.000 | CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCNC(=O)OCCOC)OC(=O)CCCCCCCCCCCCCCCCC | 250mg | 672544474
eMolecules m-PEG2-acid | Broadpharm | 149577-05-9 | MFCD09939037 | 148.158 | C6H12O4 | 98.000 | COCCOCCC(O)=O | 1g | 229582838
m-PEG2-acid | Broadpharm | 149577-05-9 | MFCD09939037 | 148.158 | C6H12O4 | 98.000 | COCCOCCC(O)=O | 1g | 229582838
Medchemexpress LLC N3-PEG3-vc-PAB-MMAE | 99.1% | 1352.66 | C67H109N13O16 | 5 MG
N3-PEG3-vc-PAB-MMAE is an azide-functionalized drug-linker for antibody-drug conjugate research that combines a PEG3 spacer, a valine-citrulline cleavable peptide with a p-aminobenzyl self-immolative spacer, and the cytotoxic payload monomethyl auristatin E (MMAE). It is designed for bioorthogonal conjugation and ADC construction, supplied as a white to off-white solid with high purity.
- Azide-functionalized for CuAAC and SPAAC conjugation.
- Peg3 spacer improves solubility and flexibility of conjugates.
- Valine-citrulline-PAB linker enables enzymatic release of payload.
- MMAE payload provides potent antimitotic activity.
- High molecular weight (1352.66) supports defined stoichiometry in ADCs.
- High purity (~99.1%) reduces impurities in conjugation reactions.
- Powder stable at -20°C (3 years) and 4°C (2 years); prepare fresh in solution.
Medchemexpress LLC Methyl-PEG4-NHS ester | 622405-78-1 | MFCD11041112 | 95.0% | 333.33 | C14H23NO8 | 10G
Methyl-PEG4-NHS ester is a methyl-capped polyethylene glycol linker terminating in an N-hydroxysuccinimide (NHS) ester. It is used for amine-targeted bioconjugation and as a flexible PEG spacer in bifunctional molecules, enabling efficient formation of stable amide bonds and improved solubility.
- Provides an NHS ester for rapid conjugation to primary amines.
- Methyl-capped PEG4 spacer increases solubility and linker flexibility.
- Suitable for PROTAC synthesis and general bioconjugation applications.
- Molecular weight 333.33 and molecular formula C14H23NO8.
- CAS number 622405-78-1 and MFCD11041112 for reference.
- Typical purity around 95.0% and available in multiple pack sizes.